Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of HER2-specific CAR-T cell therapy BP2301-01
jRCT2033220088Phase 1Recruiting
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Start
- May 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in osteosarcoma (OS), soft tissue sarcoma (STS) and gynecological cancer (2 arms), sponsored by BrightPath Biotherapeutics Co., Ltd. Primary endpoint: Dose-limiting toxicity incidence at each dose. Started May 2022; status: recruiting.
02
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)gynecological cancer
Beyond the preview
Go deeper on jRCT2033220088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033220088.